Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

INFECT · Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures that Dictate Severity of Tissue Infection

FP7Status: CLOSED1 January 201330 June 2018EU funding €11,913,591

The overall goal with INFECT is to advance our understanding of the pathophysiological mechanisms, prognosis, and diagnosis of the multifactorial highly lethal NSTIs. The fulminant course of NSTIs (in the order of hours) demands immediate diagnosis and adequate interventions in order to salvage lives and limbs. However, diagnosis and management are difficult due to heterogeneity in clinical presentation, in co-morbidities and in microbiological aetiology. Thus, there is an urgent need for novel diagnostic and therapeutic strategies in order to improve outcome of NSTIs. To achieve this, a comprehensive and integrated knowledge of diagnostic features, causative microbial agent, treatment strategies, and pathogenic mechanisms (host and bacterial disease traits and their underlying interaction network) is required. INFECT is designed to obtain such insights through an integrated systems biology approach in patients and different clinically relevant experimental models.Specific objectives of INFECT are to:1. Unravel specific mechanisms underlying diseases signatures though a bottom-up systems approach applied to clinically relevant experimental settings2. Apply a top-down systems biology approach to NSTI patient samples to pin-point key host and pathogen factors involved in the onset and development of infection3. Identify and quantify disease signatures and underlying networks that contribute to disease outcome4. Exploit identified disease traits for the innovation of optimized diagnostic tools5. Translate the advanced knowledge generated into evidence-based guidelines for classification and management, and novel therapeutic strategiesWe have gathered a team of multidisciplinary researchers, clinicians, SMEs and a patient organization, each with a unique expertise, technical platform and/or model systems that together provide the means to successfully conduct the multifaceted research proposed and efficiently disseminate/exploit the knowledge obtained.

Consortium · 16 organisations

coordinator

KAROLINSKA INSTITUTET

SE · €2,110,979

participant

REGION HOVEDSTADEN

DK · €1,607,774

participant

LIFEGLIMMER GMBH

DE · €610,354

participant

UNIVERSITE LYON 1 CLAUDE BERNARD

FR · €356,799

participant

MARSDEN DOREEN

UK · €47,445

participant

BLEKINGE LANS LANDSTING

SE · €45,197

participant

UNIVERSITY OF NORTH DAKOTA

US · €1,333,730

participant

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

DE · €1,752,400

participant

VÄSTRA GÖTALANDSREGIONEN

SE · €435,000

participant

TEL AVIV UNIVERSITY

IL · €332,000

participant

ANAGNOSTICS BIOANALYSIS GMBH

AT · €276,880

participant

WAGENINGEN UNIVERSITY

NL · €1,324,548

participant

University of Cincinnati

US · €93,737

participant

REGION STOCKHOLM

SE · €385,095

participant

CUBE DX GMBH

AT · €305,140

participant

UNIVERSITETET I BERGEN

NO · €896,513

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.